Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review

Most pituitary tumors are considered benign adenomas, and only 0.1%–0.2% of them present metastasis and are defined as pituitary carcinomas (PCs). Refractory pituitary adenomas (PAs) lie between benign adenomas and true malignant PCs and are defined as aggressive-invasive PAs, characterized by a hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Congxin, Liang, Siyu, Sun, Bowen, Li, Yong, Kang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635636/
https://www.ncbi.nlm.nih.gov/pubmed/34869016
http://dx.doi.org/10.3389/fonc.2021.773905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635636/
https://www.ncbi.nlm.nih.gov/pubmed/34869016
http://dx.doi.org/10.3389/fonc.2021.773905

Ejemplares similares